Non-small cell lung cancer is not typically inherited directly, but genetics do play a role. The vast majority of NSCLC cases are caused by mutations that develop during a person’s lifetime from environmental exposures like smoking and radon. However, roughly 15% of lung cancer patients carry inherited gene variants that may have contributed to their cancer risk, and having a first-degree relative with lung cancer can raise your own risk by 30% to 40%.
How Inherited and Acquired Mutations Differ
There are two fundamentally different ways a gene mutation can lead to cancer. Somatic mutations happen after conception in ordinary body cells. They accumulate over a lifetime from cigarette smoke, air pollution, radiation, or simple copying errors when cells divide. These mutations drive the overwhelming majority of lung cancers and cannot be passed to your children.
Germline mutations are the inherited kind. They exist in every cell of your body because they were present in the egg or sperm cell that created you. A germline mutation doesn’t guarantee you’ll develop cancer, but it can make your cells more vulnerable to the additional damage that eventually triggers it. Lung cancer is listed among the common conditions linked to somatic mutations, which is why most cases are not hereditary. But that 15% of patients who do carry inherited pathogenic gene variants represent a meaningful minority.
Genes Linked to Inherited Lung Cancer Risk
Several specific inherited gene variants have been connected to higher NSCLC risk. The most studied involve genes you may recognize from other cancers.
- EGFR germline mutations: The T790M variant has been directly linked to familial NSCLC. Among never-smoking women who carry this inherited mutation, there is a 31% probability of developing lung cancer. Three other inherited EGFR variants (V843I, R776X, and P848L) have also been identified in familial cases.
- BRCA1 and BRCA2: Most commonly associated with breast and ovarian cancer, BRCA2 mutations also increase lung cancer risk. These genes help repair damaged DNA, and when they don’t work properly, cells are more likely to accumulate the kind of errors that lead to cancer.
- CHEK2: Another DNA repair gene linked to elevated lung cancer risk.
- TP53 (Li-Fraumeni syndrome): People with this rare inherited syndrome face cancer risks 24 times higher than the general population. Lung cancer is part of the syndrome’s pattern, and when it occurs, it is overwhelmingly adenocarcinoma, the most common subtype of NSCLC. Cases tend to appear at younger ages and show a female predominance.
A large study of over 7,700 lung cancer patients found that pathogenic germline variants were especially concentrated in DNA repair genes. This makes biological sense: if your cells are less efficient at fixing DNA damage from environmental exposures, each cigarette or radon exposure carries a greater cumulative toll.
Family History and Your Risk
Even without a known gene mutation, having a family member with lung cancer is a meaningful signal. Nonsmoking individuals with a first-degree relative who had lung cancer face roughly 1.4 times the risk of developing it themselves. That number climbs sharply with age at diagnosis. For nonsmokers between 40 and 59, a positive family history is the single strongest predictor of lung cancer risk, with odds approximately seven times higher than those without family history. Interestingly, this family history effect largely disappears for nonsmokers diagnosed after age 60, suggesting that inherited susceptibility plays its biggest role in earlier-onset disease.
Children of nonsmoking lung cancer patients may carry the highest inherited risk. One study found that offspring of nonsmoking cases had about seven times the lung cancer risk compared to offspring of nonsmoking controls. These numbers come with wide confidence intervals because familial lung cancer in nonsmokers is relatively uncommon, but the pattern is consistent: the younger the diagnosis and the less environmental exposure involved, the more likely genetics are a factor.
How Genetics and Environment Interact
Inherited risk rarely operates in isolation. Your genes influence how efficiently your body handles carcinogens, which means two people with the same smoking history or radon exposure can face very different cancer risks depending on their genetic makeup.
This gene-environment interaction has been studied most closely with radon, a naturally occurring radioactive gas that seeps into homes from the ground. People who carry certain inherited variants in detoxification genes are substantially more vulnerable to radon. For example, individuals missing a functional copy of a key detoxification gene who were also exposed to high indoor radon levels (above 200 Bq/m³) had roughly 3.5 times the lung cancer risk compared to those with the functional gene and lower radon exposure. Similar patterns appear with genes involved in DNA repair: people with less effective repair mechanisms showed odds of lung cancer two to four times higher at elevated radon concentrations.
The interaction between radon and tobacco is described as “submultiplicative,” meaning the combined effect of both exposures is greater than either one alone, though not quite as extreme as multiplying the two risks together. The practical takeaway is that inherited genetic variation creates a spectrum of vulnerability. Some people’s biology offers more protection against environmental carcinogens, while others are genetically primed to be more affected by the same exposures.
Why Inherited Status Can Affect Treatment
Knowing whether a lung cancer has an inherited component isn’t just about understanding risk. It can also shape treatment. Tumors driven by mutations in DNA repair genes, whether inherited or acquired, tend to respond particularly well to a class of drugs called PARP inhibitors and to platinum-based chemotherapy. These treatments exploit the tumor’s inability to repair its own DNA, essentially turning the cancer’s weakness against it.
This approach has been well established in ovarian, breast, prostate, and pancreatic cancers with DNA repair deficiencies, and evidence is growing that the same principle applies to lung cancer. In one notable case, a patient with a lung cancer carrying an inherited DNA repair gene variant experienced marked tumor regression on a combination of a PARP inhibitor and another targeted agent. Patients whose tumors carry these inherited DNA repair variants also appear to have better recurrence-free survival, mirroring what’s seen in other cancer types.
Who Should Consider Genetic Testing
Not every lung cancer patient needs germline genetic testing, but certain patterns suggest it could be valuable. A lung cancer diagnosis before age 50, a personal or family history of multiple cancers, lung cancer in a never-smoker, or a known cancer syndrome in the family are all reasons to discuss genetic counseling. Testing can identify inherited variants that affect not only your treatment options but also the cancer risk for your blood relatives.
If you have a strong family history of lung cancer, genetic counseling can help clarify whether your family pattern reflects shared environmental exposures (like living in a high-radon area or secondhand smoke), true inherited susceptibility, or some combination. For relatives found to carry a pathogenic variant, earlier or more frequent screening with low-dose CT scans may be appropriate, particularly given that inherited lung cancers tend to appear at younger ages than typical cases.